Akero Therapeutics, Inc. (AKRO)
Akero Therapeutics, Inc.
601 Gateway Boulevard
Suite 350
South San Francisco, CA 94080
United States
650 487 6488
https://akerotx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 55
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Andrew Cheng M.D., Ph.D. | President, CEO & Director | 1.04M | 15.28M | 1967 |
| Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Executive VP, COO & Secretary | 672.35k | 584.34k | 1970 |
| Dr. Timothy Rolph | Co-Founder & Chief Scientific Officer | 722.32k | 2.16M | 1954 |
| Mr. William R. White J.D. | Executive VP, CFO, Treasurer & Head of Corporate Development | 678.06k | 839.84k | 1973 |
| Ms. Catriona Yale | Executive VP & Chief Development Officer | 678.06k | 458.9k | 1972 |
| Mr. Scott A. Gangloff | Chief Technology Officer | N/D | N/D | 1974 |
| Mr. Patrick Lamy | Senior Vice President of Commercial Strategy | N/D | N/D | 1973 |
| Mr. John J. Schembri | VP of Finance & Controller | N/D | N/D | 1962 |
Descripción
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Akero Therapeutics, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 9; Junta: 9; Derechos del accionista: 8; Compensación: 9.
